The U.S. Health and Human Services Secretary is pushing to end a rule that allows food companies to use additives that ...
Biogen Inc. ( NASDAQ: BIIB) Stifel 2025 Virtual CNS Forum Conference March 18, 2025 10:15 AM ET Great. Good morning, everybody. Happy to be moderating my annual panel where Priya has to listen to me ...
Investing.com -- The U.S. Food and Drug Administration (FDA) and the Department of Health and Human Services (HHS) unveiled a series of actions and programs on Tuesday, aimed at improving the quality, ...
The U.S. FDA and HHS announced on Tuesday a set of actions and initiatives focused on infant formula to ensure the ongoing quality, safety, nutritional adequacy and resilience of the domestic infant ...
HC Wainwright initiated coverage on Alpha Cognition, noting a new twist on a tried-and-tested treatment paradigm.
Brandon Gill and five other House Republicans filed impeachment articles against Judge James Boasberg. Only 15 federal judges ...
The Welnax BioClear Toenail Fungus Device is a cutting-edge, non-invasive laser therapy tool designed for at-home use. Unlike ...
3h
Zacks Investment Research on MSNBayer's sNDA for Kerendia Label Expansion Gets FDA's Priority ReviewBayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for ...
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for finerenone for the treatment of ...
Johnson & Johnson's nipocalimab receives FDA Fast Track status for Sjögren's disease, following strong Phase 2 trial results on disease activity and IgG reduction.
The US Food and Drug Administration (FDA) accepted and granted Priority Review designation for Bayer’s (BAYN: DE) supplemental new drug application (sNDA) for a new indication for Kerendia (finerenone ...
Despite the Trump administration's shake-up of the agency, the US FDA is the first port of call for most ASX biotechs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results